Patrick Warnat

Summary

Country: Germany

Publications

  1. pmc Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes
    Patrick Warnat
    Department of Theoretical Bioinformatics B080, German Cancer Research Center DKFZ, Im Neuenheimer Feld 280, Heidelberg, Germany
    BMC Cancer 7:89. 2007
  2. pmc Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes
    Patrick Warnat
    Department of Theoretical Bioinformatics, German Cancer Research Center, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
    BMC Bioinformatics 6:265. 2005
  3. ncbi request reprint Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer
    Olaf Thuerigen
    Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    J Clin Oncol 24:1839-45. 2006
  4. pmc Automatic identification of subcellular phenotypes on human cell arrays
    Christian Conrad
    Intelligent Bioinformatics Systems, German Cancer Research Center DKFZ, 69120 Heidelberg, Germany
    Genome Res 14:1130-6. 2004
  5. ncbi request reprint Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling
    Alexander Schramm
    Department of Pediatric Oncology and Hematology, University Hospital of Essen, Hufelandstr 55, Essen 45122, Germany
    Oncogene 24:7902-12. 2005
  6. ncbi request reprint Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome
    Matthias Fischer
    Department of Pediatric Oncology and Hematology and Center of Molecular Medicine Cologne, University Children s Hospital, Germany
    Clin Cancer Res 12:5118-28. 2006
  7. ncbi request reprint Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification
    Andre Oberthuer
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    J Clin Oncol 24:5070-8. 2006
  8. ncbi request reprint Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease
    Andre Oberthuer
    Children s Hospital, Department of Pediatric Oncology and Hematology and Center for Molecular Medicine Cologne CMMC, University of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    Cancer Lett 250:250-67. 2007

Collaborators

Detail Information

Publications8

  1. pmc Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes
    Patrick Warnat
    Department of Theoretical Bioinformatics B080, German Cancer Research Center DKFZ, Im Neuenheimer Feld 280, Heidelberg, Germany
    BMC Cancer 7:89. 2007
    ..Additional research effort is needed to describe the patterns of gene expression in this cohort and to identify reliable prognostic markers for this subset of patients...
  2. pmc Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes
    Patrick Warnat
    Department of Theoretical Bioinformatics, German Cancer Research Center, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
    BMC Bioinformatics 6:265. 2005
    ..Although similar questions for the same type of cancer are addressed in these different studies, a comparative analysis of their results is hampered by the use of heterogeneous microarray platforms and analysis methods...
  3. ncbi request reprint Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer
    Olaf Thuerigen
    Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    J Clin Oncol 24:1839-45. 2006
    ..This study was aimed at the identification of a gene expression signature in diagnostic core biopsy tissue samples that predicts pCR...
  4. pmc Automatic identification of subcellular phenotypes on human cell arrays
    Christian Conrad
    Intelligent Bioinformatics Systems, German Cancer Research Center DKFZ, 69120 Heidelberg, Germany
    Genome Res 14:1130-6. 2004
    ..Our classification method can be adapted to virtually any microscopic assay based on cell morphology, opening a wide range of applications including large-scale RNAi screening in human cells...
  5. ncbi request reprint Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling
    Alexander Schramm
    Department of Pediatric Oncology and Hematology, University Hospital of Essen, Hufelandstr 55, Essen 45122, Germany
    Oncogene 24:7902-12. 2005
    ..Our data suggest that microarray-derived data in addition to traditional clinical factors will be useful for risk assessment and defining biological properties of neuroblastoma...
  6. ncbi request reprint Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome
    Matthias Fischer
    Department of Pediatric Oncology and Hematology and Center of Molecular Medicine Cologne, University Children s Hospital, Germany
    Clin Cancer Res 12:5118-28. 2006
    ..Identification of molecular characteristics of spontaneously regressing stage IVS and progressing stage IV neuroblastoma to improve discrimination of patients with metastatic disease following favorable and unfavorable clinical courses...
  7. ncbi request reprint Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification
    Andre Oberthuer
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    J Clin Oncol 24:5070-8. 2006
    ..To develop a gene expression-based classifier for neuroblastoma patients that reliably predicts courses of the disease...
  8. ncbi request reprint Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease
    Andre Oberthuer
    Children s Hospital, Department of Pediatric Oncology and Hematology and Center for Molecular Medicine Cologne CMMC, University of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    Cancer Lett 250:250-67. 2007
    ..5%. However, patients with unfavorable outcome of MYCN non-amplified disease were largely misclassified (accuracy: 35%), suggesting that these courses are not identified by current marker genes...